Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Combination pharmacotherapies for cardiac reverse remodeling in heart failure patients with reduced ejection fraction: A systematic review and network meta-analysis of randomized clinical trials
Jieli Bao, Rongsheng Kan, Junhong Chen, et al.
Pharmacological Research (2021) Vol. 169, pp. 105573-105573
Closed Access | Times Cited: 41

Showing 1-25 of 41 citing articles:

Mechanisms of SGLT2 Inhibitors in Heart Failure and Their Clinical Value
Yafei Xie, Yujie Wei, Dan Li, et al.
Journal of Cardiovascular Pharmacology (2023) Vol. 81, Iss. 1, pp. 4-14
Closed Access | Times Cited: 34
Pharmacotherapy in patients with heart failure with reduced ejection fraction: A systematic review and meta-analysis
Jia Tang, Ping Wang, Chenxi Liu, et al.
Chinese Medical Journal (2024)
Open Access | Times Cited: 5
Heart Failure With Improved Ejection Fraction: Prevalence, Predictors, and Guideline-Directed Medical Therapy
Sheethal G Oommen, Ruzhual K Man, Keerthi Talluri, et al.
Cureus (2024)
Open Access | Times Cited: 5
Efficacy of sacubitril‐valsartan and SGLT2 inhibitors in heart failure with reduced ejection fraction: A systematic review and meta‐analysis
Xingchun Mo, Ping Lü, Xiaojing Yang
Clinical Cardiology (2023) Vol. 46, Iss. 10, pp. 1137-1145
Open Access | Times Cited: 12
Cardiac rhythm devices in heart failure with reduced ejection fraction – role, timing, and optimal use in contemporary practice. European Journal of Heart Failure expert consensus document
Biykem Bozkurt, Wilfried Müllens, C. Leclercq, et al.
European Journal of Heart Failure (2025)
Closed Access
Clinical efficacy of sacubitril/valsartan combined with cardiac rehabilitation in patients with heart failure after acute myocardial infarction: a single-center randomized trial
Yan-Mei Zhao, Jun-Ting Luo, Kai-Fang Pang, et al.
BMC Cardiovascular Disorders (2025) Vol. 25, Iss. 1
Open Access
The Role of ARNI in Enhancing Outcomes of Cardiac Resynchronization Therapy: A Comprehensive Review
Oana Pătru, Silvia Luca, Dragoş Cozma, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 8, pp. 2743-2743
Open Access
Effect of sacubitril/valsartan on cardiac remodeling compared with other renin–angiotensin system inhibitors: a difference-in-difference analysis of propensity-score matched samples
Erberto Carluccio, Frank Lloyd Dini, Michele Correale, et al.
Clinical Research in Cardiology (2023) Vol. 113, Iss. 6, pp. 856-865
Open Access | Times Cited: 9
The recent advance and prospect of natural source compounds for the treatment of heart failure
Xingjuan Chen, Siyuan Liu, Siming Li, et al.
Heliyon (2024) Vol. 10, Iss. 5, pp. e27110-e27110
Open Access | Times Cited: 3
Revascularization and outcomes in ischaemic left ventricular dysfunction after heart failure admission: The RevascHeart study
Carlos Moliner‐Abós, Maria Calvo‐Barceló, Eduard Solé‐González, et al.
European Journal of Heart Failure (2024)
Closed Access | Times Cited: 2
A review of biomarker and imaging monitoring to predict heart failure recovery
Crystal Lihong Yan, Luanda Grazette
Frontiers in Cardiovascular Medicine (2023) Vol. 10
Open Access | Times Cited: 6
Beneficial effects of flavonoids on animal models of atherosclerosis: A systematic review and meta-analysis
Gege Liao, Wanlu Liu, Yiming Dai, et al.
iScience (2023) Vol. 26, Iss. 11, pp. 108337-108337
Open Access | Times Cited: 6
Improvement in Left and Right Ventricular Function after Introduction of SGLT2 Inhibitors in Heart Failure Outpatients with Reduced Ejection Fraction
Gianmarco Alcidi, Rosanna Pugliese, Sara Ioannoni, et al.
Clinics and Practice (2023) Vol. 13, Iss. 6, pp. 1303-1312
Open Access | Times Cited: 5
Malnutrition and infection lead to poor prognosis and heavy financial burden of patients with chronic heart failure
Xu Jia, Xinglong Yu, Bin Lu, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 8
Central arterial pressure predicts in-hospital major adverse cardiovascular events after acute ST-segment elevation myocardial infarction: a retrospective cohort study
Lin Zhang, Zijian Wang, Xia Lu, et al.
Annals of Translational Medicine (2023) Vol. 11, Iss. 5, pp. 214-214
Open Access | Times Cited: 4
Sacubitril/valsartan can improve the cardiac function in heart failure patients with a history of cancer: An observational study
Zhulu Chen, Chuan Zhang, Yuxi Zhu, et al.
Medicine (2024) Vol. 103, Iss. 12, pp. e37613-e37613
Open Access | Times Cited: 1
Chinese medicinal formula Fu Xin decoction against chronic heart failure by inhibiting the NLRP3/caspase-1/GSDMD pyroptotic pathway
Lei Zhang, Yan Li, Cundong Fan, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 174, pp. 116548-116548
Open Access | Times Cited: 1
Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy
Giada Colombo, Tor Biering‐Sørensen, Joao P. Ferreira, et al.
ESC Heart Failure (2024)
Open Access | Times Cited: 1
Retrospective study on the short-term efficacy of different doses of Spironolactone in patients with heart failure of ischemic cardiomyopath and the influence of ventricular remodeling markers
Li Xie
American Journal of Cardiovascular Disease (2024) Vol. 14, Iss. 1, pp. 21-28
Open Access | Times Cited: 1
Evaluation of early left-sided cardiac reverse remodeling under combined therapy of sacubitril-valsartan and spironolactone compared with angiotensin-converting enzyme inhibitors and spironolactone
Wioletta Sacharczuk, Rafał Dankowski, Stefan Ożegowski, et al.
Frontiers in Cardiovascular Medicine (2023) Vol. 10
Open Access | Times Cited: 3
Cardiac reverse remodelling by imaging parameters with recent changes to guideline medical therapy in heart failure
M. Kodsi, D. Makarious, G. Gan, et al.
ESC Heart Failure (2023) Vol. 10, Iss. 6, pp. 3258-3275
Open Access | Times Cited: 3
Dynamic Secondary Mitral Regurgitation: Current Evidence and Challenges for the Future
Hirokazu Onishi, Masaki Izumo, Toru Naganuma, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 5
Sacubitril-valsartan modifies the indication of cardiac implantable devices in patients with heart failure and reduced ejection fraction
Laia Carla Belarte-Tornero, Diana Mojón, Eduard Solé‐González, et al.
Revista Española de Cardiología (English Edition) (2021) Vol. 74, Iss. 12, pp. 1117-1119
Open Access | Times Cited: 7
Preventive Effect Observation of Dapagliflozin on Middle and Later Ventricular Remodeling in Patients with Acute ST Segment Elevation Anterior Wall Myocardial Infarction: A Single-Center, Retrospective Cohort Study
Zeyan Liu, Lijun Liu, Hao Zhang, et al.
Journal of Healthcare Engineering (2022) Vol. 2022, pp. 1-9
Open Access | Times Cited: 4
Should HFrEF patients with NYHA class II expect benefit from CCM therapy? Results from the MAINTAINED observational study
Christian Fastner, Goekhan Yuecel, Svetlana Hetjens, et al.
Clinical Research in Cardiology (2022) Vol. 111, Iss. 11, pp. 1286-1294
Closed Access | Times Cited: 4
Page 1 - Next Page

Scroll to top